Abaloparatide excels teriparatide in protecting against alveolar bone loss in experimental periodontitis.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of periodontology"
DOI: 10.1002/jper.22-0211
Abstract: BACKGROUND It was aimed to compare the effects of two osteoanabolic drugs, abaloparatide (ABL) and teriparatide (TPTD), on protecting alveolar bone in experimental periodontitis. METHODS Twenty-four 9-week-old male Sprague-Dawley rats were placed with silk ligature… read more here.
Keywords: experimental periodontitis; abl; alveolar bone; abl tptd ... See more keywords
Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis
Sign Up to like & getrecommendations! Published in 2020 at "Osteoporosis International"
DOI: 10.1007/s00198-020-05388-y
Abstract: We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database. Differences were noted in sex, age, pathologic fractures, comorbidity index, and… read more here.
Keywords: tptd; dmab; abl tptd; patients initiating ... See more keywords